Seattle-based Oncothyreon (NASDAQ: [[ticker:ONTY]]) has named Scott D. Myers its new president and CEO. Myers most recently ran Aerocrine, a diagnostics company that Circassia Pharmaceuticals bought for $214 million last year. He also had stints at UCB and Johnson & Johnson before that. Christopher Henney had been serving as Oncothyreon’s interim CEO after Robert Kirkman retired in January. Myers will take over for Henney on April 4.
Author: Ben Fidler
Ben is former Xconomy Deputy Editor, Biotechnology. He is a seasoned business journalist that comes to Xconomy after a nine-year stint at The Deal, where he covered corporate transactions in industries ranging from biotech to auto parts and gaming. Most recently, Ben was The Deal’s senior healthcare writer, focusing on acquisitions, venture financings, IPOs, partnerships and industry trends in the pharmaceutical, biotech, diagnostics and med tech spaces. Ben wrote features on creative biotech financing models, analyses of middle market and large cap buyouts, spin-offs and restructurings, and enterprise pieces on legal issues such as pay-for-delay agreements and the Affordable Care Act. Before switching to the healthcare beat, Ben was The Deal's senior bankruptcy reporter, covering the restructurings of the Texas Rangers, Phoenix Coyotes, GM, Delphi, Trump Entertainment Resorts and Blockbuster, among others. Ben has a bachelor’s degree in English from Binghamton University.
View all posts by Ben Fidler